KRAS and ovarian cancer: In fact, other mechanisms have been suggested in other types of tumors, as CHD5 mutation or methylation is associated with KRAS or BRAF mutation in ovarian cancer [11], and CHD5 expression correlates with MYCN amplification in neuroblastoma [7,25].